Moderna, Inc. (MRNA)
Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz
Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
How to Play Moderna Stock After the Recent Sales Guidance Cut
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (MRNA -2.72%). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.
Is Moderna a Bad-News Buy for 2025?
Moderna (MRNA 0.90%) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped the stock to skyrocket, reaching a high of more than $480 at its peak in 2021.
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Moderna (MRNA 0.90%) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
A bad seven-month stretch just got worse for Moderna (MRNA -1.96%). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Moderna (MRNA) settling at $34.45, representing a -1.98% change from its previous close.
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion.
